Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Q4 FY2023 Earnings Presentation
25 slides from Valiant Organics's earnings presentation, May 20, 2023
Slide 1: Exchange filing cover letter for investor presentation
May 20, 2023 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai- 400 001. G Block Bandra-Kurla Complex, Bandra (E), Mumbai- 400 051. SCRIP CODE - 540145 S
Slide 2: Earnings Presentation | Q4-FY23/FY23
Earnings Presentation | Q4-FY23/FY23
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f
Slide 4: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 5: Chemistries And Product Basket
Chemistries And Product Basket FY23 Revenue Share Hydrogenation Ammonolysis 46% Key Products: Industries Served: Key Products: • Ortho Anisidine • Dyes Industries Served: • Para Anisidine • Pigments • Para Nitro Aniline • Dyes • Ortho Chloro Para Nitro Aniline • IPPCA • Pharmaceutical • Pigments • M
Slide 6: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 28,800 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 7: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 8: Capex Projects
Capex Projects Product Project Status Remarks Commissioned • Currently, limited availability domestically and mostly imported Para Amino Phenol (PAP) Completed in Q4 FY’21 • Ramp up in the production ongoing to achieve the target by the end of FY’24 • Multi-purpose plant for forward integration with
Slide 9: Q4-FY23/FY23 Highlights
Q4-FY23/FY23 HIGHLIGHTS Valiant Organics Limited |Q4-2023 8
Slide 10: Consolidated Financial Highlights
CONSOLIDATED FINANCIAL HIGHLIGHTS Q4-FY23 Consolidated Financial Highlights FY23 Consolidated Financial Highlights INR 2,714 Mn INR 10,518 Mn Operational Revenue Operational Revenue INR 523 Mn INR 1,643 Mn Operating EBITDA Operating EBITDA 19.27% 15.62% Operating EBITDA Margin Operating EBITDA Margi
Slide 11: Q4-FY23/FY23 Operational Highlights
Q4-FY23/FY23 Operational Highlights Q4-FY23 Revenue Break-up – Chemistries • Q4-FY23 witnessed a significant improvement in terms of revenue and margins due to Others, 6% improvement in orders from the Sarigam unit, which was in recovery mode after the fire incident. Chlorination, Ammonolysis, 24% •
Slide 12: Key Chemistries: Sales Volumes and Revenues
Key Chemistries Chlorination Hydrogenation Ammonolysis Others REVENUES (INR Mn) 1, 140 1,128 853 257 900 300 900 788 1, 120 800 612 250 800 700 545 1, 100 700 579 1,076 501 600 200 138 600 1, 080 500 107 500 150 400 1, 060 1,045 400 300 100 300 1, 040 200 200 50 1, 020 100 100 0 0 0 1, 000 Q4-FY22 Q
Slide 13: Quarterly Consolidated Financial Performance
Quarterly Consolidated Financial Performance Particulars (INR Mn) Q4-FY23 Q4-FY22 Y-o-Y Q3-FY23 Q-o-Q Revenue from Operations 2,714 3,476 (21.9)% 2,504 8.4% Total Expenses 2,191 2,906 (24.6)% 2,121 3.3% EBITDA 523 570 (8.2)% 383 36.6% EBITDA Margins (%) 19.27% 16.40% 287 Bps 15.30% 397 Bps Other Inc
Slide 14: Annual Consolidated Financial Performance
Annual Consolidated Financial Performance Particulars (INR Mn) FY23 FY22 Y-o-Y Revenue from Operations 10,518 11,533 (8.8)% Total Expenses 8,875 9,484 (6.4)% EBITDA 1,643 2,049 (19.8)% EBITDA Margins (%) 15.62% 17.77% (215) Bps Other Income 80 74 8.1% Depreciation 292 296 (1.4)% Finance Cost 108 65
Slide 15: Quarterly Standalone Financial Performance
Quarterly Standalone Financial Performance Particulars (INR Mn) Q4-FY23 Q4-FY22 Y-o-Y Q3-FY23 Q-o-Q Revenue from Operations 2,272 2,906 (21.8)% 2,176 4.4% Total Expenses 1,831 2,463 (25.7)% 1,892 (3.2)% EBITDA 441 443 (0.5)% 284 55.3% EBITDA Margins (%) 19.41% 15.24% 417 Bps 13.05% 636 Bps Other Inc
Slide 16: Annual Standalone Financial Performance
Annual Standalone Financial Performance Particulars (INR Mn) FY23 FY22 Y-o-Y Revenue from Operations 9,116 9,484 (3.9)% Total Expenses 7,817 7,811 0.1% EBITDA 1,299 1,673 (22.4)% EBITDA Margins (%) 14.25% 17.64% (339) Bps Other Income 29 33 (12.1)% Depreciation 276 273 1.1% Finance Cost 105 64 64.1%
Slide 17: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW Valiant Organics Limited |Q4-2023 16
Slide 18: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY20 FY21* FY22* FY23* Operational Income 6,749 7,548 11,533 10,518 Total Expenses 4,946 5,496 9,484 8,875 EBITDA 1,803 2,052 2,049 1,643 EBITDA Margins (%) 26.71% 27.19% 17.77% 15.62% Other Income 63 59 74 80 Depreciation 158 212 296 292
Slide 19: Consolidated Balance Sheet (IND-AS)
Consolidated Balance Sheet (IND – AS) Particulars (INR Mn) FY21 FY22 FY23 Particulars (INR Mn) FY21 FY22 FY23 EQUITY 5,086 6,489 7,401 Non-Current Assets 5,731 6,652 7,682 a) Equity Share Capital 272 272 272 a) Property, Plant and Equipment 4,967 5,303 6,565 b) Other Equity 4,747 5,856 6,616 c) Righ
Slide 20: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY20 FY21* FY22* FY23* Revenue from Operations 5,836 5,742 9,484 9,116 Total Expenses 4,103 4,170 7,811 7,817 EBITDA 1,733 1,572 1,673 1,299 EBITDA Margins (%) 29.69% 27.38% 17.64% 14.25% Other Income 52 169 33 29 Depreciation 130 186 273 2
Slide 21: Standalone Balance Sheet (IND-AS)
Standalone Balance Sheet (IND – AS) Particulars (INR Mn) FY21 FY22 FY23 Particulars (INR Mn) FY21 FY22 FY23 EQUITY 5,023 6,031 6,661 Non-Current Assets 5,798 6,787 7,424 a) Equity Share Capital 272 272 272 a) Property, Plant and Equipment 4,771 5,085 6,092 b) Other Equity 4,747 5,755 6,385 b) Right-
Slide 22: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 80.00% 1,282 1,309 1,279 2,052 1, 400 2,049 14, 000 11,533 2,100 1,803 70.00% 10,518 1,026 12, 000 1,800 1,643 1, 100 10, 000 60.00% 1,500 50.00% 7,548 800 8, 000 6,749
Slide 23: Capital Market Information
Capital Market Information Share Price up to 31st March, 2023 20% 10% 0% -10% -20% -30% -40% -50% -60% -70% Apr-22 May-22 Jun-22 Jul-22 Aug-22 Sep-22 Oct-22 Nov-22 Dec-22 Jan-23 Feb-23 Mar-23 Valiant Organics - Closing Price Sensex Shareholding pattern (As on 31st March 2023) Price Data (As on 31st
Slide 24: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 25: Thank You
THANK YOU Valiant Organics Limited |Q4-2023 24